Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.
about
A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].Tigecycline: a review of a new glycylcycline antibioticPharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsPharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsEffect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infectionsA randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsTigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistanceOritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapyTigecycline: a new glycylcycline for treatment of serious infections.Current use of anti-infectives in dermatology.Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.Tigecycline for the treatment of infections due to resistant Gram-positive organisms.Tigecycline: a novel glycylcycline antibiotic.In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyTreatment options for multidrug-resistant bacteria.Investigational treatments for postoperative surgical site infections.Tigecycline does not prolong corrected QT intervals in healthy subjects.Current concepts in antibiotic-resistant gram-negative bacteria.Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality controlAntibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecyclineComparative activities of tigecycline and other tetracyclines against nonfermenting Gram-negative bacilli, excluding Acinetobacter spp.Metallo-β-lactamase-producing Enterobacteriaceae isolates at a Taiwanese hospital: lack of distinctive phenotypes for screening.Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report.Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals.Illumina short-read and MinION long-read WGS to characterize the molecular epidemiology of an NDM-1 Serratia marcescens outbreak in Romania.In vitro activity of tigecycline against Bacteroides species.Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004-2009).
P2860
Q24813784-225AD0DC-45E3-422A-9083-E226368CC359Q28278979-C119AC20-22D6-4563-B552-BB0D4D450779Q29398341-65CF1BCE-E359-4EB5-BC21-743081D91BC2Q33722056-3DB7F9F6-D961-46B1-B1E1-977D4A4E087AQ33935354-7CA65E92-A63F-489C-A094-4825F39CA3F2Q34123811-1F7FCE82-0EF6-4D1B-8BB5-CFD1DD640508Q34352287-A1740B63-C69D-4885-A303-7972B1614A4DQ34474973-5B7B2ADD-AB8F-467C-93B7-09363D35914FQ34803735-FA366F97-D000-4C90-92B6-943C22AFF58EQ35007097-8C9F5468-0271-42A8-86F7-05B69D653AB6Q35637071-E1B241AA-8300-4673-B5EF-3AD9A8A31575Q35960920-0511C391-F135-48BE-BBCD-FB4C3586F781Q36218312-4BB9516D-74AB-4CDA-A29A-06CEF8E68444Q36233506-687A14BE-6CA6-42C1-A7E2-9D4A9889AFDCQ36312068-BD5D7B37-37E6-407A-B370-A577D61D933FQ36376443-B8D2051E-04E9-40F9-8777-D6924E04D885Q36379330-8A5B8B44-599D-4401-9DA1-E9DFE4E6D91BQ36509591-DFCBC1A4-A592-4C2C-8A36-CC3E65F08523Q36607401-CDC0AEF0-4072-4793-A881-730FB7819640Q36715742-1C4EB595-2D19-4616-8DAA-8C10E548DC1BQ36757583-E9B270BA-168C-42E0-9ACF-76F18EB2BCD3Q36960068-B2A73BA7-64DA-4881-A60A-69DCDD646D1DQ37071179-D80A03FD-8594-4908-878F-8BB00F5720D6Q37593094-E9DC4366-DD4B-49E4-BB43-4CCA95FAC880Q37838117-A9887409-9768-4618-ABB8-A1B48C720A33Q37940546-FCD78B68-CC07-405A-878A-CAEDE4C1B247Q38665257-665CAAE0-D159-4AEC-B377-D83847763308Q39792528-17A9F70E-4926-4B0F-A855-4AD295606157Q40241381-0E7CE8F7-4D31-4EA0-887E-ACD732BC76CFQ41337352-BBBE4451-998A-4D1E-AAD3-1571ABCDDD42Q42085642-2A0857EA-FE99-42B8-8BA1-B596A64C3C9BQ42432332-AF79294D-83A6-49AF-B4E4-88C2229C0004Q42549433-A37A8B8B-4544-4F8A-9870-132D19DC2606Q42698160-B0C7F4EF-DA92-4C83-B54F-730DAF07AB2FQ43716670-CBC8D8C5-8B7B-48D5-A562-7BD664B7C02BQ45945756-7C205590-AA56-4AA3-B06C-63DD1E829527Q46144628-228A966A-54B9-42AB-8286-A60C534875DFQ46242040-54E44EFF-8920-4FF2-A223-38CCB487A71FQ46542090-1024ECAC-DE60-496A-99FF-40AC84D43AE7Q46556054-00BFAA9D-61D3-4C39-A903-7134C06979F7
P2860
Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@en
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@nl
type
label
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@en
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@nl
prefLabel
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@en
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@nl
P2093
P2860
P1476
Activities of the glycylcyclin ...... n clinical bacterial isolates.
@en
P2093
D Milatovic
F-J Schmitz
P2860
P304
P356
10.1128/AAC.47.1.400-404.2003
P407
P577
2003-01-01T00:00:00Z